Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.49 |
| ▸ | CDK1 | P06493 | 10/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | PI4KA | P42356 | 1/20 | 0.42 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.42 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 8/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.39 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
| ▸ | PRKACG | P22612 | 1/20 | 0.39 |
| ▸ | PRKACB | P22694 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20656163 | 0.83 | CDK1 (0.51) | CDK2CDK1CCNB1CCNE1ADORA2A | |
| SCHEMBL13057431 | 0.81 | CDK1 (0.50) | CDK2CDK1CCNB1CCNE1ADORA2A | |
| SCHEMBL1293109 | 0.80 | CDK2 (0.49) | CDK2CDK1CCNB1CCNE1ADORA2A | |
| SCHEMBL21540017 | 0.80 | CDK1 (0.71) | CDK2CDK1CCNB1CCNE1ADORA2A | |
| SCHEMBL14039518 | 0.80 | CDK1 (0.71) | CDK2CDK1CCNB1CCNE1ADORA2A | |
| SCHEMBL31707890 | 0.80 | CDK2 (0.49) | CDK2CDK1CCNB1CCNE1ADORA2A | |
| SCHEMBL24181537 | 0.78 | CDK2 (0.46) | CDK2CDK1CCNB1CCNE1ADORA2A | |
| SCHEMBL23027205 | 0.77 | CDK1 (0.42) | CDK2CDK1CCNB1CCNE1ADORA2A | |
| SCHEMBL15046609 | 0.76 | CDK2 (0.45) | CDK2CDK1CCNB1CCNE1ADORA2A | |
| SCHEMBL18751223 | 0.74 | ADORA2A (0.64) | CDK2CDK1CCNB1CCNE1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11576968-B2 | Hepatitis C virus immunogenic compositions and methods of use thereof | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-02-14 | — | — | US | disclosed |
| US-20210170018-A1 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2021-06-10 | — | — | US | disclosed |
| US-10881726-B2 | Hepatitis C virus immunogenic compositions and methods of use thereof | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2021-01-05 | — | — | US | disclosed |
| US-20190231867-A1 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2019-08-01 | — | — | US | disclosed |
| US-10357560-B2 | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants | BROCK UNIVERSITY (CA) | 2019-07-23 | — | — | US | disclosed |
| US-20190015502-A1 | USE OF FLUORINATED CYCLIC DINUCLEOTIDES AS ORAL VACCINE ADJUVANTS | BROCK UNIVERSITY (CA) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210170018-A1 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | HAVCR2, CD74, DNAJC10 | CDK2 3360/4885CDK1 3695/4885CCNB1 2079/4885 |
| US-10881726-B2 | Hepatitis C virus immunogenic compositions and methods of use thereof | HAVCR2, CD74, DNAJC10 | CDK2 3360/4885CDK1 3695/4885CCNB1 2079/4885 |
| US-20190231867-A1 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | HAVCR2, CD74, DNAJC10 | CDK2 3360/4885CDK1 3695/4885CCNB1 2079/4885 |
| US-10357560-B2 | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants | TLR9, CGAS, DUT | CDK2 4522/4885CDK1 4800/4885CCNB1 4043/4885 |
| US-20190015502-A1 | USE OF FLUORINATED CYCLIC DINUCLEOTIDES AS ORAL VACCINE ADJUVANTS | TLR9, CGAS, DUT | CDK2 4522/4885CDK1 4800/4885CCNB1 4043/4885 |
| US-11576968-B2 | Hepatitis C virus immunogenic compositions and methods of use thereof | HAVCR2, CD74, DNAJC10 | CDK2 3360/4885CDK1 3695/4885CCNB1 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.